Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: PepTools vendor-neutral scientific reference catalog
Also known as: PF-06882961, danuglipron free acid, Danuglipron [USAN], danuglipron [INN]
Danuglipron is a nonpeptide, orally administered small-molecule agonist of the human glucagon-like peptide-1 receptor. Its chemical identity is associated with molecular formula C31H30FN5O4, molecular weight 555.6 g/mol, and CAS Registry Number 2230198-02-2. Clinical studies evaluated immediate-release and modified-release oral formulations, including twice-daily regimens in type 2 diabetes and obesity. Pfizer announced discontinuation of danuglipron development on April 14, 2025, following review of clinical data and regulatory input after a participant in a dose-optimization study experienced potential drug-induced liver injury.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Evidence-backed clinical regimens included oral danuglipron 2.5, 10, 40, 80, or 120 mg twice daily with food for 16 weeks in a phase 2b type 2 diabetes study; higher-dose groups used weekly escalation steps. A phase 2a study evaluated escalation to target doses of 80, 120, or 200 mg twice daily. A phase 2b obesity study evaluated twice-daily dosing escalated to 40-200 mg twice daily over 26 or 32 weeks. These are historical study regimens only and are not prescribing or administration recommendations. Pfizer discontinued development on April 14, 2025. No reliable authoritative source was identified for a generally applicable compound half-life, onset, solubility, or storage specification.
Supplementary research context only. Not medical advice or a treatment recommendation.
CAS RN 2230198-02-2; molecular formula C31H30FN5O4; molecular weight 555.6 g/mol; PubChem CID 134611040; FDA UNII DN9IUI24GP; InChIKey HYBAKUMPISVZQP-DEOSSOPVSA-N; IUPAC name 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]-2-pyridinyl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid
Clinical studies reported gastrointestinal adverse events, including nausea, vomiting, diarrhea, and dyspepsia. Phase 2b obesity studies reported substantial treatment discontinuation, frequently associated with adverse events. Pfizer reported one asymptomatic participant in a once-daily dose-optimization study with potential drug-induced liver injury that resolved after discontinuation; development was subsequently discontinued.
Reflects published research. Educational reference — not a recommendation for use.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention danuglipron or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.